Tolmar Opens New Laboratory at Rosalind Franklin University

On December 16, 2025, Tolmar, Inc., a specialty pharmaceutical company, officially opened its new Northern Illinois Laboratory at the Innovation and Research Park (IRP) of Rosalind Franklin University in North Chicago, Illinois. This facility enhances Tolmar’s capacity for developing and commercializing pharmaceutical products, while also enriching the university’s innovation ecosystem.

Founded in 2007, Tolmar is recognized internationally for its advanced long-acting injectable drug delivery capabilities. The company specializes in creating and manufacturing long-acting injectables in critical areas including urology, oncology, and endocrinology. Its leading product, employed in the treatment of advanced prostate cancer, is marketed in 89 countries.

Expansion of Development Capabilities

The new laboratory at Rosalind Franklin’s IRP is designed to complement the existing team of researchers and operations staff based in Colorado. This expansion will not only enhance Tolmar’s research and development capabilities but will also solidify its regional presence, which includes executive offices and sales personnel located in Buffalo Grove, Illinois.

Dr. Dave Loffredo, vice president of innovation at Tolmar, expressed enthusiasm about the new facility, stating, “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois. After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”

Dr. Stace Porter, the company’s senior vice president of development operations, highlighted the significant potential of the new lab within the university’s research park. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores. Surrounded by Lake County’s vibrant network of global life science companies, we’re excited to grow and innovate here,” he said.

Collaboration and Innovation

The state-of-the-art, 100,000-square-foot IRP houses six research centers, including the Center for Cancer Cell Biology, Immunology and Infection. Dr. Joseph DiMario, executive vice president for research at Rosalind Franklin University, expressed optimism about the partnership. “We look forward to collaborations that can help accelerate new product development,” he noted. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”

As Tolmar sets up its new laboratory, it joins a network of leading organizations dedicated to advancing pharmaceutical research and development. With its focus on oncology, urology, and endocrinology, Tolmar aims to leverage its new facility to enhance its contributions to these critical fields.

For further information about Tolmar and its initiatives, visit www.tolmar.com. To learn more about Rosalind Franklin University and its programs, go to rosalindfranklin.edu.